Related Experiment Video
Updated: Aug 18, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
The effect of triiodothyronine on glucose utilization in adipocytes from obese rats
1Food and Nutrition Department, Iowa State University, Ames 50011.
Abstract:
1. In the presence of insulin, 10(-5) M 3,3',5-triiodothyronine (T3) treatment for 1/2 hr decreased fatty acid synthesis 35% only in adipocytes from lean rats, whereas at 10(-11) M through 10(-7) M T3 the obese adipocytes had nearly a 20% increase in fatty acid synthesis. 2. A 2 hr pretreatment of adipocytes with 10(-9) and 10(-7) M T3 decreased insulin-stimulated fatty acid synthesis by nearly 20% in both lean and obese adipocytes. 3. In the absence of insulin, the 2 hr pretreatment with 10(-9) M T3 resulted in a 45% increase in lean adipocyte fatty acid synthesis, though the obese adipocytes required at least 10(-7) M T3 for 2 hr to increase the non-insulin-stimulated fatty acid synthesis by 50%. 4. At 10(-9) M T3 concentrations non-insulin-stimulated fatty acid synthesis was increased by 200% in lean adipose tissue explants, but obese adipose explants were not significantly affected under these conditions. 5. The addition of 10(-9) M T3 plus insulin to the explant media decreased fatty acid synthesis by 35% in both the lean and obese tissues. 6. The results also imply that the low T3 status of the obese rat may be contributory to the elevated fatty acid synthesis observed in obese adipocytes.
More Related Videos
10:35Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
Published on: April 6, 2022
04:54Using a Combination of Indirect Calorimetry, Infrared Thermography, and Blood Glucose Levels to Measure Brown Adipose Tissue Thermogenesis in Humans
Published on: June 2, 2023
Related Concept Videos
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Type II Diabetes II: Pathophysiology